Share on StockTwits

United Therapeutics (NASDAQ:UTHR) is set to announce its Q114 earnings results on Tuesday, April 29th. Analysts expect the company to announce earnings of $1.65 per share and revenue of $300.14 million for the quarter.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Tuesday, February 25th. The company reported $2.88 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.51 by $1.37. The company had revenue of $289.02 million for the quarter, compared to the consensus estimate of $295.43 million. On average, analysts expect United Therapeutics to post $6.95 EPS for the current fiscal year and $8.44 EPS for the next fiscal year.

United Therapeutics (NASDAQ:UTHR) opened at 90.87 on Monday. United Therapeutics has a 1-year low of $61.23 and a 1-year high of $116.65. The stock has a 50-day moving average of $95.06 and a 200-day moving average of $96.58. The company has a market cap of $4.587 billion and a price-to-earnings ratio of 28.51.

A number of research firms have recently commented on UTHR. Analysts at Standpoint Research upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, April 7th. They now have a $118.00 price target on the stock. On the ratings front, analysts at Zacks downgraded shares of United Therapeutics from an “outperform” rating to a “neutral” rating in a research note on Friday, April 4th. They now have a $98.00 price target on the stock. Finally, analysts at Wedbush raised their price target on shares of United Therapeutics from $114.00 to $119.00 in a research note on Wednesday, April 2nd. Six equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $95.50.

In other United Therapeutics news, CEO Martine A. Rothblatt sold 9,066 shares of the company’s stock on the open market in a transaction that occurred on Thursday, April 24th. The stock was sold at an average price of $92.45, for a total transaction of $838,151.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.